Market Cap 183.99M
Revenue (ttm) 146.07M
Net Income (ttm) -196.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -134.21%
Debt to Equity Ratio -0.40
Volume 613,300
Avg Vol 500,356
Day's Range N/A - N/A
Shares Out 18.34M
Stochastic %K 80%
Beta 0.21
Analysts Strong Sell
Price Target $15.33

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 658 0600
Address:
85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 12:25 AM
$KPTI RSI: 82.23, MACD: 0.8270 Vol: 1.51, MA20: 7.73, MA50: 7.35 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ppl_first
ppl_first Feb. 24 at 6:52 PM
$KPTI Next meaningful catalyst - Additional combination trial data updates and commercial sales trajectory. There is no dramatic Phase 3 surprise scheduled imminently. This is more of an execution and revenue story now. It tends to spike on data and then fade.
1 · Reply
celebratelife
celebratelife Feb. 24 at 2:46 PM
$KPTI KPTI $15 Soon On The Way To $300+. Just my opinion.
1 · Reply
_PantherC
_PantherC Feb. 24 at 12:51 AM
•@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. •If you’re not paying attention yet, you’re missing out. Go give him a follow. It’s completely free and only takes a second 💎 $QUIK $AUST $KPTI $RMSG also on my wl
0 · Reply
celebratelife
celebratelife Feb. 23 at 7:55 PM
$KPTI - another double bullish huge short-put long call trade, and other very bullish trades. Options market seems to be predicting more than a double for the stock by March OpEx.
0 · Reply
celebratelife
celebratelife Feb. 23 at 6:52 PM
$KPTI Major indices down. XBI up. KPTI up another 5+% on the way to $300+ on data and firing of CEO Richard Paulson. Two possibly block buster readouts coming up for KPTI. Should see $15 soon and $50+ soon after. ​$XBI $SPY $QQQ $DJIA
0 · Reply
celebratelife
celebratelife Feb. 23 at 5:15 AM
$KPTI How much of our money lousy CEO Richard Paulson is willing to give away to be in another photo opp with Dempsey? He gave away multiple 250k+ donations of OUR money that he raised from toxic financing since he's run a HUGE deficit with no financial disciple for years, with free catered lunches for everyone, unnecessary travels, plush vacation club type of "culture" with more benefits than most companies in the USA, and wasting millions in these and other ways we have documented. Dempsey Center told me personally about the company's splurging HUGE donations, north of $250,000 a shot which NEVER translated into value for shareholders. That is the profile of our CEO Richard Paulson, and the Board who's stood behind him and are just as bad. Shorts love those KPTI value destroyers who've apparently felt no sense of accountability, but each of them, including some executive directors can and will be held personally financially liable and accountable.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 21 at 4:04 PM
$DAWN appears the textbook example of the futility of commercial-stage bios "going it alone" versus exiting via M&A to maximize shareholder value. DAWN's Ojemda is patented through June 23, 2035 after which time it is probable Ojemda's list price, and hence revenues to support DAWN's business, will fall 85% consistent with peer cancer therapies. For example, CTIC management projected Vonjo revenues to fall 83% the year after Vonjo's patent expiration. The graph documents cumulative DAWN/Ojemda analyst consensus revenue estimates by year through 12/31/34 (when DAWN will have 6 months patent protection remaining). It is visually obvious the odds are DAWN's valuation, absent a patent extension, will otherwise decrease year after year like other peer 1 product companies $PBYI & $KPTI Of course DAWN could beat the odds. Otherwise, based on the graph, is there reason to believe Ojemda will be more valuable @ 12/31/29 when it has 5 years patent life remaining? $XBI $IBB
3 · Reply
celebratelife
celebratelife Feb. 20 at 9:18 PM
$KPTI Double bullish option trade today, same person betting stock will be over 20.05 in March (bought 17.5 call at ask), and, sold the 10 put.
0 · Reply
InkaTwits
InkaTwits Feb. 20 at 7:42 PM
$KPTI The bear case is facing a massive reality check in March. Let’s look at the math regarding the SENTRY Phase 3 blinded data (61 pts) versus Ruxolitinib standard of care. The Setup (2:1 Randomization): Approximately 41 patients on Sentry Combo (Selinexor + Ruxo) Approximately 20 patients on Ruxo Monotherapy The Safety Comparison: Standard Ruxolitinib: Historically shows approximately 12% discontinuation and 15% G3/4 Thrombocytopenia. SENTRY Blinded Group: Management reported aggregate safety results better than Phase 1, with a 12-month median exposure. The Engineering Stress Test: Even if we assume 100% of the aggregate 10% discontinuation rate came exclusively from the Selinexor arm: Selinexor Rate: Approximately 14.6% This is nearly identical to Ruxolitinib alone. If the combo safety profile matches the monotherapy, but delivers double the efficacy (79% SVR35 vs. 35% Ruxo historic), the clinical value is undeniable.
1 · Reply
Latest News on KPTI
Karyopharm to Participate in Baird's Biotech Discovery Series

Dec 8, 2025, 7:00 AM EST - 2 months ago

Karyopharm to Participate in Baird's Biotech Discovery Series


Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 24, 2025, 8:40 AM EST - 1 year ago

Karyopharm Announces 1-for-15 Reverse Stock Split


Karyopharm to Participate at Upcoming Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Karyopharm to Participate at Upcoming Investor Conferences


OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 12:25 AM
$KPTI RSI: 82.23, MACD: 0.8270 Vol: 1.51, MA20: 7.73, MA50: 7.35 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ppl_first
ppl_first Feb. 24 at 6:52 PM
$KPTI Next meaningful catalyst - Additional combination trial data updates and commercial sales trajectory. There is no dramatic Phase 3 surprise scheduled imminently. This is more of an execution and revenue story now. It tends to spike on data and then fade.
1 · Reply
celebratelife
celebratelife Feb. 24 at 2:46 PM
$KPTI KPTI $15 Soon On The Way To $300+. Just my opinion.
1 · Reply
_PantherC
_PantherC Feb. 24 at 12:51 AM
•@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. •If you’re not paying attention yet, you’re missing out. Go give him a follow. It’s completely free and only takes a second 💎 $QUIK $AUST $KPTI $RMSG also on my wl
0 · Reply
celebratelife
celebratelife Feb. 23 at 7:55 PM
$KPTI - another double bullish huge short-put long call trade, and other very bullish trades. Options market seems to be predicting more than a double for the stock by March OpEx.
0 · Reply
celebratelife
celebratelife Feb. 23 at 6:52 PM
$KPTI Major indices down. XBI up. KPTI up another 5+% on the way to $300+ on data and firing of CEO Richard Paulson. Two possibly block buster readouts coming up for KPTI. Should see $15 soon and $50+ soon after. ​$XBI $SPY $QQQ $DJIA
0 · Reply
celebratelife
celebratelife Feb. 23 at 5:15 AM
$KPTI How much of our money lousy CEO Richard Paulson is willing to give away to be in another photo opp with Dempsey? He gave away multiple 250k+ donations of OUR money that he raised from toxic financing since he's run a HUGE deficit with no financial disciple for years, with free catered lunches for everyone, unnecessary travels, plush vacation club type of "culture" with more benefits than most companies in the USA, and wasting millions in these and other ways we have documented. Dempsey Center told me personally about the company's splurging HUGE donations, north of $250,000 a shot which NEVER translated into value for shareholders. That is the profile of our CEO Richard Paulson, and the Board who's stood behind him and are just as bad. Shorts love those KPTI value destroyers who've apparently felt no sense of accountability, but each of them, including some executive directors can and will be held personally financially liable and accountable.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 21 at 4:04 PM
$DAWN appears the textbook example of the futility of commercial-stage bios "going it alone" versus exiting via M&A to maximize shareholder value. DAWN's Ojemda is patented through June 23, 2035 after which time it is probable Ojemda's list price, and hence revenues to support DAWN's business, will fall 85% consistent with peer cancer therapies. For example, CTIC management projected Vonjo revenues to fall 83% the year after Vonjo's patent expiration. The graph documents cumulative DAWN/Ojemda analyst consensus revenue estimates by year through 12/31/34 (when DAWN will have 6 months patent protection remaining). It is visually obvious the odds are DAWN's valuation, absent a patent extension, will otherwise decrease year after year like other peer 1 product companies $PBYI & $KPTI Of course DAWN could beat the odds. Otherwise, based on the graph, is there reason to believe Ojemda will be more valuable @ 12/31/29 when it has 5 years patent life remaining? $XBI $IBB
3 · Reply
celebratelife
celebratelife Feb. 20 at 9:18 PM
$KPTI Double bullish option trade today, same person betting stock will be over 20.05 in March (bought 17.5 call at ask), and, sold the 10 put.
0 · Reply
InkaTwits
InkaTwits Feb. 20 at 7:42 PM
$KPTI The bear case is facing a massive reality check in March. Let’s look at the math regarding the SENTRY Phase 3 blinded data (61 pts) versus Ruxolitinib standard of care. The Setup (2:1 Randomization): Approximately 41 patients on Sentry Combo (Selinexor + Ruxo) Approximately 20 patients on Ruxo Monotherapy The Safety Comparison: Standard Ruxolitinib: Historically shows approximately 12% discontinuation and 15% G3/4 Thrombocytopenia. SENTRY Blinded Group: Management reported aggregate safety results better than Phase 1, with a 12-month median exposure. The Engineering Stress Test: Even if we assume 100% of the aggregate 10% discontinuation rate came exclusively from the Selinexor arm: Selinexor Rate: Approximately 14.6% This is nearly identical to Ruxolitinib alone. If the combo safety profile matches the monotherapy, but delivers double the efficacy (79% SVR35 vs. 35% Ruxo historic), the clinical value is undeniable.
1 · Reply
Watson66
Watson66 Feb. 20 at 4:43 PM
$KPTI this thing doesn’t really want to stay down. 🚀
1 · Reply
PortfolioZenith
PortfolioZenith Feb. 20 at 1:27 PM
$KPTI Karyopharm Therapeutics markets oncology drugs. Revenue growth depends on adoption. Pipeline execution remains critical.
0 · Reply
celebratelife
celebratelife Feb. 19 at 11:19 PM
$KPTI Half a million buy volume last hour. The strong volume + price rise last days is very healthy technically. Problem is Richard Paulson being as horrible of a CEO as he is may have mistaken 9.60 price as being back to where he was hired!! But there was a RSS, so the price needs to be 15 times higher to get back to before this lousy CEO took over (~ $150/ share) and before that he was a lousy director with the lousy Board, the stock was $375/share before these value destroyers killed it by mismanagement.
0 · Reply
celebratelife
celebratelife Feb. 19 at 8:02 PM
$KPTI These prices are jokes - or rather nightmares. KPTI needs to go to $50 on the way to $300 for this incompetent or compromised Board and CEO to have a chance at not getting personally sued for everything they have, for alleged breach of duties that has resulted in decimation of KPTI while they gave themselves big money, and even gave away money we didn't have to Dempseys et al, which they had raised in toxic financing leaving us with a huge interest burden because they are incompetent, irresponsible, or compromised.
0 · Reply
celebratelife
celebratelife Feb. 19 at 7:56 PM
$KPTI Someone bought $10 call for tomorrow today betting it'll be over $10.35 tomorrow. And a ton of puts will expire worthless tomorrow, so whoever sold those puts (bullish move) pockets the premium.
0 · Reply
celebratelife
celebratelife Feb. 18 at 9:30 PM
$KPTI Paulson/Mano/Greene, rest of the value destroyers got the additional shares authorized to sustain their fkn salaries+ at our cost. They've paralyzed the company by mismanagement and alleged breach of duties, splurging, wasting assets, not thinking about their duty to create value, lack of financial discipline for years: splurge, dilute, when shares ran out of juice: toxic financing - and even give away that money. Shorts love these enemies of shareholders. I've never come across such irresponsible, unethical, pathetic public company CEO and Board who don't give a damn about shareholders, and their mandate to create company value. This stock was $240 fucking dollars when I first bought it and now it's struggling to keep above $9. That's all we need to know about Richard Paulson, Mike Mano, Barry Greene, Garen Bohlin, Chen Schor, Deepa Pakianathan, Zhen Su, Mansoor Mirza, Christy Oliger, Mike Mason, who've destroyed KPTI while making tons of money themselves.
0 · Reply
celebratelife
celebratelife Feb. 18 at 9:19 PM
$KPTI Clear March options bet on price being above $18+
0 · Reply
celebratelife
celebratelife Feb. 18 at 4:58 PM
0 · Reply
celebratelife
celebratelife Feb. 18 at 2:48 PM
$KPTI 9.45 5k bid followed with some trades in 9.60's and the 5k bid moved to 9.60 and was filled. Right now the spread is 50 cents!!!!
0 · Reply
FonsieTrader
FonsieTrader Feb. 18 at 10:53 AM
$KPTI over $10.00
1 · Reply
StealthStrike
StealthStrike Feb. 18 at 8:08 AM
$KPTI Karyopharm Therapeutics is a commercial-stage oncology biotech facing competition and need to expand drug label [citation:historical].
0 · Reply
celebratelife
celebratelife Feb. 18 at 6:39 AM
$KPTI This stock has a long way to go to get the lousy CEO/BoD off the legal hook. Many are holding since the stock was 300+ on down, trusting this lousy governance, all of whom including Paulson were on the Board at the time the stock was over $300 in addition to Mansour Mirza who is still allegedly liable and accountable for breach of duties like the rest of them. Just Oliger and Zu joined later but stock has tanked on their watch too as they've proven to be just as useless as the others, while all of them have paid themselves a ton of our money, and even on their watch - all of them including Mirza, Oliger and Zu and Paulson and his lousy CFO Mike Mason destroyed the company financially by mismanagement, breach of duties that did not stop the splurging / demand financial discipline. Paulson/Mason gave multiple 250k+ donations to charity from funds we did not have and were borrowed in toxic financing which would not have been necessary if the spending diarrhea had been contained.
0 · Reply